USP 药典论坛刊出 <1049.1> 生物技术产品与生物制品稳定性研究章节草案并征求意见
USP Chapter <1049.1> Stability Studies for Biotechnological and Biological Products
USP 在药典论坛 PF 51.4 中刊出 <1049.1> 生物技术产品与生物制品稳定性研究章节草案,征求意见截至 2025 年 9 月 30 日。草案分七个部分,涵盖稳定性策略与设计、各研发阶段的生命周期应用、容器与储存条件、扩展稳定性研究、统计评估及上市后变更。长期储存通常为 5 °C 或以下,并辅以加速(25 °C 或 30 °C)和强降解(37 °C 或 40 °C)条件。
USP Chapter <1049.1> is divided into several core areas that address the stability assessment of biologics - both in drug substance (DS) and drug product (DP) form - across all development phases. 1. Stability strategy and designThis chapter describes how stability programmes are designed based on storage conditions, product type (e.g. recombinant proteins, mAbs), product formulation and container. Long-term storage is usually at 5 °C or below, supplemented by accelerated (25 °C or 30 °C) and stress conditions (37 °C or 40 °C). 2. Life cycle-related applicationPreclinical phase: Use of simple but meaningful studies, often with only one batch. Early clinical phases: Real-time data is necessary, e.g. to support clinical shelf life claims and ensure patient safety. Late clinical phases: Requires at least three batches from a commercially representative process. Approval and market application: Includes comprehensive stability testing, including temperature cycles, agitation, light stability, cumulative studies and in-use scenarios. 3. Containers, storage conditions and material representativenessThis chapter emphasises the importance of representative primary packaging (e.g. glass vials, syringes) and its storage orientation (e.g. upright vs. inverted) which may affect product stability. Humidity control is important for certain types of packaging, such as semi-permeable bags.4. Extended stability studiesAdditional studies are recommended, such as: Temperature changes (e.g. transport conditions) Agitation Light stability In-use stability (e.g. after reconstitution or application) Studies on combination products (e.g. autoinjectors, on-body injectors) 5. Statistics and evaluationStability data are analysed using statistical models (e.g. linear, non-linear) to derive expiry dates with statistically justified confidence intervals. The chapter also distinguishes between shelf life estimation and stability trending and describes the procedure for out-of-trend (OOT) results. 6. Application for post-approval changesStability data support regulatory changes after market approval. This chapter provides approaches for risk-based reductions in the number, duration, or conditions of stability studies.7. Validation and selection of test methodsOnly stability-indicating methods that can detect changes are permitted. Special requirements apply to potency tests, e.g. in biological assays. Methods must be tailored to specific degradation pathways.USP chapter <1049.1> from draft USP PF 51.4 provides comprehensive, practical guidance on conducting stability studies of biotechnology products. For full context and regulatory compliance, refer to the complete draft available on the official USP website. Public comments are accepted until 30 September 2025
来源:ECA GMP News · gmp-compliance.org